Pharming Group: all proposals Annual General Meeting of Shareholders approved
Corporate updatesPharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.
Pharming Group reports financial results for the first quarter of 2022
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2022.
Pharming Group Notice of Q1 2022 Results
Financial updatesPharming confirms it will announce financial results for the first quarter of the year ended 31 March 2022 on Thursday, 12 May 2022.
Pharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for leniolisib from UK MHRA
Operational updatesAn agreed Paediatric Investigation Plan (PIP) is the regulatory pathway to market authorization for leniolisib as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children. A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA’s Early Access to Medicines Scheme
Pharming announces change in its holding in BioConnection following a substantial investment by new investor
Financial updatesFollowing an agreed investment by European investment company Gimv, Pharming’s minority stake of 43.85% in BioConnection will reduce to 22.98%. As a result of this transaction, Pharming will receive one-off US$ 7.5 million (EUR 6.9 million) net cash proceeds.
Pharming announces the filing of its 2021 Annual Report, with Form 20-F also filed with the U.S. Securities and Exchange Commission and convenes its 2022 AGM
Corporate updatesPharming announces the filing of its Annual Report for the year ended 31 December 2021. The Company has also filed its Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the same period. In addition, the company convenes its 2022 AGM.
Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting
Conference attendancePharming Group announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a primary immunodeficiency.
Pharming Announces Presentation of Positive Results of Phase III Leniolisib Trial in APDS at Clinical Immunology Society 2022 Annual Meeting
Conference attendancePharming announces that Principal Investigator V. Koneti Rao, MD, FRCPA, a staff physician in the Primary Immune Deficiency Clinic at the National Institutes of Health in Bethesda, Maryland, will present positive findings from the Phase III pivotal clinical trial of leniolisib for patients with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) at the Clinical Immunology Society (CIS) 2022 Annual Meeting in Charlotte, North Carolina.
Pharming Group reports financial results for full year 2021
Financial updatesPharming Group presents its preliminary financial report for the full year ended December 31, 2021.
Pharming Group Notice of 2021 Full Year Results
Corporate updatesPharming confirms it will announce its preliminary (unaudited) financial report for the full year 2021 on Thursday, March 17, 2022